Pre-made Otlertuzumab benchmark antibody ( di-scFv+Fc, anti-CD37 therapeutic antibody, Anti-GP52-40/TSPAN26 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Otlertuzumab biosimilar, di-scFv+Fc, Anti-CD37 Antibody: Anti-GP52-40/TSPAN26 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Otlertuzumab (TRU-016) is a humanized monoclonal antibody that targets CD37 designed for the treatment of cancer.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-416-1mg	1mg	Inquiry
GMP-Bios-ab-416-10mg	10mg	Inquiry
GMP-Bios-ab-416-100mg	100mg	Inquiry
GMP-Bios-ab-416-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Otlertuzumab biosimilar, di-scFv+Fc, Anti-CD37 Antibody: Anti-GP52-40/TSPAN26 therapeutic antibody
INN Name	Otlertuzumab
Target	CD37
Format	di-scFv+Fc
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	Trubion Pharmaceuticals;Aptevo Therapeutics
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma
Development Tech	ADAPTIR Monospecific Platform